Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ ALLG NHL 24 randomised controlled trial.
暂无分享,去创建一个
M. J. van den Bent | M. Taphoorn | H. Achterberg | M. Smits | L. Dirven | J. Zijlstra | J. Doorduijn | D. Brandsma | H. Schouten | T. Seute | J. Bromberg | R. Enting | S. Issa | K. Bakunina | M. Beijert | M. van der Meulen | G. Cull | E. Habets | E. J. Habets
[1] W. Stevens,et al. Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] D. Gladstone,et al. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab , 2019, Journal of Neuro-Oncology.
[3] D. Correa,et al. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation , 2019, Journal of Neuro-Oncology.
[4] K. Hoang-Xuan,et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Stevens,et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. , 2019, The Lancet. Oncology.
[6] M. J. van den Bent,et al. Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review. , 2018, The Lancet. Oncology.
[7] F. Cavalli,et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. , 2017, The Lancet. Haematology.
[8] O. Visser,et al. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015 , 2017, Leukemia.
[9] D. Correa,et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. , 2015, Blood.
[10] M. Taphoorn,et al. The association between cognitive functioning and health-related quality of life in low-grade glioma patients. , 2014, Neuro-oncology practice.
[11] D. Correa,et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Maron,et al. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma , 2013, Neurology.
[13] B. Schmand,et al. Nederlandse leestest voor volwassenen , 2012 .
[14] D. Tranel,et al. Neuropsychological assessment, 5th ed. , 2012 .
[15] M. Taphoorn,et al. Compromised health-related quality of life in patients with low-grade glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Villano,et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma , 2011, British Journal of Cancer.
[17] L. Douw,et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up , 2009, The Lancet Neurology.
[18] Wiro J. Niessen,et al. White matter lesion extension to automatic brain tissue segmentation on MRI , 2009, NeuroImage.
[19] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[20] D. Correa,et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] W. Sturm,et al. Neuropsychological assessment , 2007, Journal of Neurology.
[22] Jelle Jolles,et al. The Letter Digit Substitution Test: Normative Data for 1,858 Healthy Participants Aged 24–81 from the Maastricht Aging Study (MAAS): Influence of Age, Education, and Sex , 2006, Journal of clinical and experimental neuropsychology.
[23] J. Armitage,et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] K. Fliessbach,et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma , 2005, Neurology.
[25] E. Neuwelt,et al. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. , 2005, AJNR. American journal of neuroradiology.
[26] J. Menten,et al. Cognitive status and quality of life after treatment for primary CNS lymphoma , 2004, Neurology.
[27] D. Correa,et al. Cognitive functions in survivors of primary central nervous system lymphoma , 2004, Neurology.
[28] J. Jolles,et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study , 2002, The Lancet.
[29] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[30] P. Scheltens,et al. A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.
[31] P. Ingrand,et al. Primary intracerebral malignant lymphoma: report of 248 cases. , 2000, Journal of neurosurgery.
[32] L. Deangelis,et al. Long-term survival in primary CNS lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Reitan. Trail Making Test: Manual for Administration and Scoring , 1992 .
[34] B Schmand,et al. [The Dutch Reading Test for Adults: a measure of premorbid intelligence level]. , 1991, Tijdschrift voor gerontologie en geriatrie.
[35] F. Verhage. Intelligentie en leeftijd : onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar , 1964 .